FT – Ten Esports Predictions Worth Looking Forward To!

 


Ten Esports Predictions Worth Looking Forward To!

 

Globally, esports revenues are predicted to grow to $1,084 million in 2021. In terms percentage terms, that’s expected growth of 14.5% from $947.1 million in 2020.

The global average revenue per esports fan will be $4.63 this year, up +2.8% from $4.40 in 2020. Note that this is down from 2019’s $4.86 per esports enthusiast.  Newzoo.com, by which most of these predictions were made, expects it to reach $5.25 in 2021 after live events are restored.

Media rights and sponsorship is expected to bring in $833.6 million in revenues during 2021. This would represent 75% of total revenue from this industry. 

The global games’ live-streaming audience is expected to hit 728.8 million this year (2021). That is 10% growth from 2020.

The largest growth in live broadcast last year was in the Spanish and Portuguese language market. This places them after English as the most-watched languages on live-streaming platforms. Spanish grew by +369% to reach 1.4 billion hours watched, while Portuguese grew by +189% to 1.1 billion hours.

Globally, the total esports audience should grow to 474.0 million people in 2021. That’s a predicted YOY growth of +8.7%.

China is expected to have the most esports fans in 2021, with 92.8 million. They’ll be followed by the U.S. and Brazil. China should also be the largest market for live-streaming games live, with an audience of 193.0 million in 2021.

China is expected to be the largest esports entertainment market by revenues, with total revenues increasing by 14% to of $360.1 million in 2021. North America follows with predicted total revenues of $243.0 million, and Western Europe, with revenues of $205.8 million.

The League of Legends World Championship was 2020’s biggest tournament based on live viewership hours on Twitch and YouTube, with a total of 91.9 million hours. League of Legends Champions Korea was the most-watched league by live viewership hours on Twitch and YouTube, generating 53.8 million hours.

The global average revenue per esports enthusiast will be $4.63 this year, up +2.8% from $4.40 in 2020. It is important to note this is down from 2019’s $4.86 per esports enthusiast, but we expect it to jump up to $5.25 in 2021 after live events are restored.

Attend Live:

Virtual Road Show Series – Wednesday March 31 @ 1pm EDT

Join Esports Entertainment Group (GMBL) CEO Grant Johnson for this exclusive corporate presentation, followed by a Q & A session moderated by Michael Kupinski, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Register Now  |  View All Upcoming Road Shows

 

Source: 2021 Newzoo 10 Global Esports & Live Streaming Market Report 2021 PRESS COPY Key Takeaways

 

More to Discover on Channelchek:

College Scholarships for Esports Gamers

How to Invest in Esports

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

How Does the Esports Industry Make Money?

 


Esports: Show me the Money!

 

The pandemic has had both a positive and negative impact on esports and live-streaming markets. One positive result of lockdowns is they produced a spike in viewership across streaming platforms; more people at home allowed for an acceleration of the fan base as an increasing number of consumers discovered games on Twitch, YouTube, and Huya. These platforms became hubs for social interaction as well as competitive entertainment. The live-streaming market, in esports-related viewership, flourished.

On the negative side, the pandemic caused the cancelation of in-person events, which largely eliminated ticket revenues and produced lower than expected merchandise sales across the board. These factors presented challenges to arena and homestand ventures, slowing or completely stalling investor interest in related companies. The expected return to more in-person events could provide an opportunity to investors in companies involved in ticket sales sponsorship deals.

Stakeholders

There are various businesses and activities that could be included when defining esports.  The sector is still growing and finding its place in collegiate, professional and semi-professional organized tournaments by leagues that bestow prize money or title upon victory. Esports’ overall market size as it relates to investors has the largest revenues and viewership from professional competitive gaming.

With many different interested parties in the business, each plays a unique part in the broad, varied community. The largest stakeholders include broadcast platforms, game publishers, teams, consumers, athletes, sponsors, and advertisers.  From the consumer’s point of view, they tend to be fans of one broadcasting platform over another.

Revenue Generators

Revenue streams within the industry are generated from the sale of sponsorships, media rights, digital, streaming, tickets, merchandising, hosting, and publisher fees. Another revenue stream comes from rights sold to the media, inclusive of revenues generated through media property, including all revenues paid to industry stakeholders to secure the rights to show esports content on a channel. This includes payments from online streaming platforms to organizers broadcasting their content, foreign broadcasters securing rights to show content in their country or copyright costs to show video content or photos of an esports competition — an example could include Torque Esports Corp. (MLLLF). Another that involves itself in racing esports production is Engine Media Holdings (GAME:CA). Merchandise and ticket revenue is revenue generated by the sale of tickets for live esports events and merchandise. Merchandise is sold by esports teams and event organizers and sometimes includes merchandise sold by publishers.
Revenues from exchange style wagering on events in a licensed, regulated and secure platform, an example of a company involved is Esports Entertainment Group (GMBL). Digital revenue is when revenue is generated from digital sales of in-game items that utilize Team IP or signed player likeness. Teams and organizers generate revenues through sponsorship contracts. This could include deals relating to sponsoring an event, or team sponsorship, product placement, and payments by brands for team logos, etc.

 

Virtual Road Show Series – Wednesday March 31 @ 1pm EDT

Join Esports Entertainment Group (GMBL) CEO Grant Johnson for this exclusive corporate presentation, followed by a Q & A session moderated by Michael Kupinski, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Register Now  |  View All Upcoming Road Shows

 

Take-Away

There is both opportunity and a great deal to know about esports as a potential growth investment opportunity. There are different revenue streams for all the various stakeholders and some vertically integrated companies that benefit from many different streams. As a source of information visit the Travel and Leisure industry on Channelchek for information, and if you aren’t registered to receive daily research and articles, your no-cost opportunity is here.

 

More to Discover on Channelchek:


eSports Entertainment Group, NobleCon17 Presentation (Video)


The Future of Cannabis



Will Robinhood be Fined on Charges of Gamification

What’s the Timeline for a Digital Currency?


 

 

Sources:

https://www.jumpstartmag.com/leveling-up-in-the-post-pandemic-esports-market/

https://www.forbes.com/sites/mikeozanian/2018/10/23/the-worlds-most-valuable-esports-companies-1/?sh=659587a96a6e

http://resources.newzoo.com/2018-global-esports-market-report-light

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – CanAlaska Uranium (CVVUF)(CVV:CA) – Deals Manibridge Nickel Project in Thompson Nickel Belt Manitoba


CanAlaska Deals Manibridge Nickel Project in Thompson Nickel Belt Manitoba

D Block Discoveries has Staged Option to Earn up to 100% Interest; CanAlaska to be Initial Project Operator

Focus on Advancing High-Grade Sulphide Nickel Discovery

Vancouver, Canada, March 30, 2021 – CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) (“CanAlaska” or the “Company”) is pleased to announce that it has entered into a Letter of Intent (“LOI”) with D Block Discoveries Inc. (“DBD”), a private company wholly owned by Ore Group Inc., to allow DBD to earn up to 100% interest in CanAlaska’s 100%-owned 4,368 hectare Manibridge Nickel Project in Manitoba, Canada (the “Project”) (Figure 1).

DBD may earn up to a 100% interest in the Project by undertaking work and payments in three defined earn-in stages. DBD may earn an initial 49% interest (“Stage 1”) in the Project by paying the Company $30,000 cash, issue $275,000 worth of common shares and incur $500,000 in exploration expenditures on the Project within 12 months of TSX Venture Exchange approval date. DBD may earn an additional 21% interest (“Stage 2”) in the Project by paying to the Company a further $50,000 cash, issue a further 1,500,000 common shares in DBD, and incur an additional $1,500,000 in exploration expenditures on the Project within 12 months of entering the Stage 2 option. DBD may earn an additional 30% interest (“Stage 3”) in the Project by paying to the Company a further $100,000 cash, issue a further 5,000,000 common shares in DBD, and incur an additional $2,000,000 in exploration expenditures on the Project within 24 months of entering the Stage 3 option.

After successful completion of either of Stage 1 or Stage 2 of the option agreement, and if DBD elects to not enter the final stage, a joint venture will be formed and the parties will either co-contribute on a simple pro-rata basis or dilute on a pre-defined straight-line dilution formula. A summary of the various stages is contained in Table 1.

During Stage 1 and Stage 2 of the option agreement, CanAlaska will be operator of the Project. DBD will have sole voting rights on exploration programs while sole funding at the various option stages and will have the right to assume operatorship after successfully earning 70% interest in the Project (Stage 2).

As part of completing the Stage 1 option, DBD will grant to CVV a 1% Net Smelter Return (NSR) royalty on claims P1271F and P1272F, and a 2% NSR royalty on all other claims.

Table 1: Summary of Option Stages

Option Stage DBD
Interest
Earned
(%)
Cash
Payment
($)
DBD Shares
Issued
Exploration
Expenditure
($)
Timeline
(months)
On signing 15,000
On CPC merger 15,000 $100,000 eq. On TSX Approval
Stage 1 49 $175,000 eq. 500,000 12
Stage 2 21 50,000 1,500,000 1,500,000 12
Stage 3 30 100,000 5,000,000 2,000,000 24
Totals 100 180,000 6,500,000* 4,000,000 36


*Does not include the $275,000 worth of share issuance

Manibridge Nickel Project

The Manibridge nickel deposit was discovered in 1963 by Falconbridge (as Glencore was then named) following up on coincident magnetic and electromagnetic anomalies that were thought to be caused by an ultramafic body. The second hole of the program intersected the fringes of what would become the Manibridge Mine. Sulphide nickel mineralization is hosted within an elongate, folded ultramafic body that extends for at least 3.2 kilometres with nickel-bearing sulphide mineralization throughout (Figure 1). The Manibridge nickel deposit is located within the core of a major fold axis with up to ten sulphide lenses that conform to the fold pattern and plunge to depths in excess of 380 metres.

A production decision was made in 1969 on an initial mineral inventory of 1,409,000 tons (including 15% dilution) at an average grade of 2.25% nickel and 0.27% copper to a depth of 380 metres. The mine was operational from 1971 to 1977 with concentrate shipped to both Sudbury, Ontario and Thompson, Manitoba. Mining occurred to a depth of 300 metres and the mine infrastructure has since been reclaimed.


Manibridge Project – Location and Geology Map

In 2007, Crowflight Minerals Inc. and Pure Nickel formed a 50-50% joint venture to explore the Manibridge claims. The 2008 exploration program intersected two new zones of nickel mineralization within 400 metres of the Manibridge deposit. Further drilling confirmed the extension of the mineralization below the mine workings. The most significant results from drill holes MN08-01, MN08-02 and MN08-04 respectively include: 16.75 metres (55 feet) @ 1.38% Ni; 5.45 metres (17.9 feet) @ 1.18% Ni; and 6.3 metres (20.7 feet) @ 1.37% Ni.

In 2019 a 800 metre drill program completed by CanAlaska 2.5 kilometres north along the mine trend intersected a broad fold structure that included multiple high-grade nickel assays up to 12.06% nickel,

CanAlaska President, Peter Dasler, comments, “CanAlaska is pleased to be able to work with D-Block’s entrepreneurial group, and management is looking forward to operating the next exploration programs and new discoveries at Manibridge, as well as being exposed to the new company’s other exploration interests.”

About D Block Discoveries

D Block Discoveries Inc. is privately held wholly owned private company controlled by Ore Group Inc. DBD controls the Strange Nickel Project, an 11,000-hectare, drill permitted nickel, copper, PGE exploration property west of Thunder Bay, Ontario. DBD is planning its going public process for listing on the TSX Venture Exchange in the near term. Further information can be found at DBD’s website.

Other News

CanAlaska is currently conducting drilling at its 100% owned Waterbury Uranium project in the Athabasca Basin near the Cigar Lake uranium mine. The Company is also awaiting drill results from its Mouse Mountain copper property in British Columbia, and drilling permits for the Strong nickel project in Manitoba.

About CanAlaska Uranium

CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres), in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.” CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds. For further information visit www.canalaska.com.

The qualified technical person for this news release is Dr Karl Schimann, P. Geo, CanAlaska director and VP Exploration.

On behalf of the Board of Directors

“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President & CEO
CanAlaska Uranium Ltd.

Contacts:

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: [email protected]

Cory Belyk, COO
Tel: +1.604.688.3211 x 138
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Release – Seanergy Maritime (SHIP) – Acquires its 15th Capesize Vessel and Receives Bank Commitment Letter


Seanergy Maritime Acquires its 15th Capesize Vessel and Receives Bank Commitment Letter

 

GLYFADA, Greece, March 30, 2021 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company”) (NASDAQ: SHIP) announced today that it has entered into a definitive agreement with an unaffiliated third party to purchase a modern Capesize vessel (the “Vessel”). Upon delivery of this acquisition, as well as the previously announced vessel purchases, the size of the Company’s fleet will increase to 15 Capesize vessels with an aggregate cargo capacity of approximately 2.65 million dwt.

The Vessel was built in 2012 at a reputable shipyard in Japan, has a cargo-carrying capacity of approximately 181,300 deadweight tons (“dwt”) and shall be renamed M/V Hellasship. The Vessel is expected to be delivered towards the end of April 2021, subject to the satisfaction of certain customary closing conditions. The ballast water system installation of the Vessel was completed by the current owner and, therefore, no additional costs are envisaged for the Vessel to comply with the relevant regulations. The gross purchase price of $28.6 million is expected to be funded with cash at hand or by a combination of cash at hand and proceeds from new loan facilities.

In addition, the Company received a commitment letter from a European Bank for a $15.5 million loan facility secured by two of its Capesize vessels, the M/V Goodship and the M/V Tradership. The loan will have a tenor of four years from the drawdown date and will bear interest at 4.0% plus LIBOR per annum. The loan remains subject to customary conditions precedent and execution of definitive documentation. Seanergy is also in advanced discussions with leading financial institutions for further financing transactions at competitive terms.

 

Stamatis Tsantanis, the Company’s Chairman & Chief Executive Officer, stated:

“We are pleased to announce the agreement to acquire our 15th Capesize vessel, which will grow our fleet by 50% within the last 9 months. The planning of all our recent acquisitions has been well-timed in light of significantly improved market conditions, which attests to our position as a leading pure-play Capesize company.

Given the prompt delivery prospects, the Company is expected to benefit from the rapidly increasing freight rates. The average of the Baltic Capesize Index currently stands at about $19,000 per day, while the Capesize forward freight contracts (“FFA”) for the second quarter and second half of 2021 are trading at above $22,000 per day on average. Based on these FFA rates, the incremental net revenue from the four recently announced acquisitions may exceed $21 million for the remainder of the year, based on their planned delivery schedule.

Moreover, the new debt financing with the competitive underlying cost, will provide additional liquidity supporting our efforts to successfully execute on our strategic goal of sustainable growth and improved shareholder returns.

The improved prospects of the Capesize market are expected to continue for the coming years and based on our expanded fleet and advantageous employment arrangements, we strongly believe that Seanergy is very well-positioned to benefit from this trend.”

 

Company Fleet upon Vessels’ delivery:

Vessel Name

Vessel Class

Capacity (DWT)

Year Built

Yard

Employment

Partnership

Capesize

179,213

2012

Hyundai

T/C Index Linked

Championship

Capesize

179,238

2011

Sungdong

T/C Index Linked

Lordship

Capesize

178,838

2010

Hyundai

T/C Index Linked

Premiership

Capesize

170,024

2010

Sungdong

T/C Index Linked

Squireship

Capesize

170,018

2010

Sungdong

T/C Index Linked

Knightship

Capesize

178,978

2010

Hyundai

T/C Index Linked

Gloriuship

Capesize

171,314

2004

Hyundai

T/C Index Linked

Fellowship

Capesize

179,701

2010

Daewoo

T/C Index Linked

Geniuship

Capesize

170,058

2010

Sungdong

T/C Index Linked

Goodship

Capesize

177,536

2005

Mitsui Engineering

Voyage/Spot

Leadership

Capesize

171,199

2001

Koyo – Imabari

Voyage/Spot

Tradership

Capesize

176,925

2006

Japanese Shipyard

N/A

Flagship

Capesize

176,387

2013

Japanese Shipyard

N/A

Patriotship

Capesize

181,709

2010

Japanese Shipyard

N/A

Hellasship

Capesize

181,325

2012

Japanese Shipyard

N/A

Total / Average age

2,642,463

11.9

 

About Seanergy Maritime Holdings Corp.

Seanergy Maritime Holdings Corp. is the only pure-play Capesize ship-owner publicly listed in the US. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. Upon delivery of the new vessels, the Company’s operating fleet will consist of 15 Capesize vessels with an average age of 11.9 years and aggregate cargo carrying capacity of approximately 2,642,463 dwt.

The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”, its Class A warrants under “SHIPW” and its Class B warrants under “SHIPZ”.

Please visit our company website at: www.seanergymaritime.com

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s ability to continue as a going concern; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations outside the United States; risks associated with the length and severity of the ongoing novel coronavirus (COVID-19) outbreak, including its effects on demand for dry bulk products and the transportation thereof; and other factors listed from time to time in the Company’s filings with the SEC, its most recent annual report on Form 20-F. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

Seanergy Investor Relations
Tel: +30 213 0181 522
E-mail: [email protected]

Capital Link, Inc.
Daniela Guerrero
230 Park Avenue Suite 1536
New York, NY 10169
Tel: (212) 661-7566
E-mail: [email protected]

Release – Genprex (GNPX) – Preclinical Data for TUSC2 Immunogene Therapy in NSCLC to Be Featured


Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 AACR Annual Meeting

 

Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib 

AUSTIN, Texas — (March 30, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell lung cancer (NSCLC), will be featured in two presentations at the upcoming annual meeting of the American Association for Cancer Research (AACR 21) taking place virtually from April 9-14, 2021.  

“We look forward to the presentation of these data that highlight the potential of TUSC2 immunogene therapy to enhance chemo-immune combination treatments and overcome resistance to osimertinib in lung cancer, to an audience of the world’s leading cancer researchers,” said Rodney Varner, President and Chief Executive Officer of Genprex. “As lung cancer is the leading cause of cancer deaths worldwide, we remain keenly focused on initiating our Acclaim-1 and Acclaim-2 clinical trials to evaluate REQORSA, our proprietary TUSC2 immunogene therapy, in non-small cell lung cancer.”  

Acclaim-1 is a Phase 1/2 combination clinical trial using REQORSA combined with AstraZeneca’s Tagrisso® (osimertinib) in patients with late-stage NSCLC whose disease progressed after treatment with Tagrisso. Acclaim-2 is a Phase 1/2 combination clinical trial using REQORSA combined with Merck & Co’s Keytruda® (pembrolizumab) in NSCLC patients who are low expressors of PD-L1.    

Featured Genprex-supported abstracts to be presented at AACR 21 include: 

Oral Presentation

Session: MS.IM02.02 – Overcoming Resistance in the Tumor Microenvironment: Novel Immunomodulatory Agents

Title: “TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robus antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice”

Poster Number/Channel: #76/Channel 03

Presentation Date/Time: April 10, 2021 from 2:50-3:00 p.m. ET

Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX

Poster Presentation

Session: PO.ET03.01 – Drug Resistance in Molecular Targeted Therapies

Title: “Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC”

Poster Number: #1105

Presentation Date/Time: April 10, 2021 from 8:30 a.m. – 11:59 p.m. ET

Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Lihui Gao, Meng Feng, Huiqin Chen, Min Jin Ha, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of REQORSA and our other potential product candidates including whether we receive or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
[email protected]

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
[email protected]

Release – Endeavor Silver (EXK) – Announces Board and Management Succession Plans

 


Endeavour Silver Announces Board and Management Succession Plans

 

VANCOUVER, British Columbia, March 30, 2021 (GLOBE NEWSWIRE) — Endeavour
Silver Corp. (TSX: EDR, NYSE: EXK)
(“Endeavour”) announces its forthcoming board and management succession plans.

In anticipation of the re-election of the current directors as proposed in the Management Information Circular for the Annual General Meeting (“AGM”) of Shareholders to be held on May 12, 2021, Geoff Handley, Chair of Endeavour, plans to step down as the Chair of the Board of Directors but will remain active as a Director. Rex McLennan will become the Lead Independent Director at that time.

Bradford Cooke, Chief Executive Officer and Director, has been invited by the Board to assume the role of Executive Chair of Endeavour, and plans to step down as the CEO immediately following the AGM. Dan Dickson, Chief Financial Officer, has been nominated to assume the role of CEO of Endeavour, and Christine West, Vice President Controller, has been nominated to assume the role of CFO of Endeavour.

Bradford Cooke commented, “I am pleased to announce this seamless board and management transition without having to reach outside of the organization. It speaks to the depth of our management team, and the skills and dedication they bring to the Company. I look forward to supporting Dan and Christine in their new roles, and we appreciate the vote of confidence of our Board of Directors.”

“I plan to stay active with Endeavour, utilizing my knowledge of and contacts in the mining industry to continue building a bigger and better Company. However, given that Endeavour is now preparing for its next phase of growth, starting with the construction of the Terronera project this year, now is an appropriate time to pass the baton to our rising stars in management.”

About Endeavour Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that owns and operates three high-grade, underground, silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision and exploring its portfolio of exploration and development projects in Mexico and Chile to facilitate its goal to become a premier senior silver producer. Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Contact Information
Galina Meleger, Director Investor Relations
Toll free: (877) 685-9775
Tel: (604) 640-4804
Email: [email protected]
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook, Twitter, Instagram and LinkedIn

Cautionary Note Regarding Forward-Looking Statements

This
news release contains “forward-looking statements” within the meaning of the
United States private securities litigation reform act of 1995 and
“forward-looking information” within the meaning of applicable Canadian
securities legislation. Such forward-looking statements and information herein
include but are not limited to statements regarding Endeavour’s anticipated
performance in 2021 including changes in mining operations and production
levels, the timing and results of various activities and the impact of the
COVID 19 pandemic on operations. The Company does not intend to and does not
assume any obligation to update such forward-looking statements or information,
other than as required by applicable law. 

Forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity, production
levels, performance or achievements of Endeavour and its operations to be
materially different from those expressed or implied by such statements. Such
factors include but are not limited to the ultimate impact of the COVID 19
pandemic on operations and results, changes in production and costs guidance,
national and local governments, legislation, taxation, controls, regulations
and political or economic developments in Canada and Mexico; financial risks
due to precious metals prices, operating or technical difficulties in mineral
exploration, development and mining activities; risks and hazards of mineral
exploration, development and mining; the speculative nature of mineral
exploration and development, risks in obtaining necessary licenses and permits,
and challenges to the Company’s title to properties; as well as those factors
described in the section “risk factors” contained in the Company’s most recent
form 40F/Annual Information Form filed with the S.E.C. and Canadian securities
regulatory authorities.

Forward-looking statements
are based on assumptions management believes to be reasonable, including but
not limited to: the continued operation of the Company’s mining operations, no
material adverse change in the market price of commodities, mining operations
will operate and the mining products will be completed in accordance with
management’s expectations and achieve their stated production outcomes, and
such other assumptions and factors as set out herein. Although the Company has
attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements or
information, there may be other factors that cause results to be materially
different from those anticipated, described, estimated, assessed or intended.
There can be no assurance that any forward-looking statements or information
will prove to be accurate as actual results and future events could differ
materially from those anticipated in such statements or information.
Accordingly, readers should not place undue reliance on forward-looking
statements or information.

Release – Namaste Technologies (NXTTF)(N:CA) – Reports Year End 2020 Financial Results


Namaste Technologies Reports Year End 2020 Financial Results

 

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) — Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, today reported its financial results for the year ended November 30, 2020. All financial figures are in Canadian dollars unless otherwise indicated.

Highlights of Consolidated Financial Results:

  • Gross revenue for the fourth quarter ended November 30, 2020 was $8.0 million (compared to $4.0 million in the same period last year), and for the fiscal year ended November 30, 2020 was $27.1 million (compared to $16.4 million in the fiscal year ended November 30, 2019), representing an increase of 100% from the same quarter last year and an increase of 65% from the prior year, respectively.
  • Net revenue for the quarter ended November 30, 2020 was $7.2 million (compared to $3.9 million in the same period last year), and for the fiscal year ended November 30, 2020 was $25.1 million (compared to $16.3 million in the fiscal year ended November 30, 2019), representing an increase of 85% from the same quarter last year, and an increase of 54% from the prior year, respectively.
  • The $3.3 million improvement in net revenue for the fourth quarter ended November 30, 2020 over the same quarter in the prior year ($8.8 million YTD) was primarily attributable to the increased revenues from the sale of cannabis products.
  • The Company’s net loss has shown substantial improvement as compared to 2019. Net loss for the fourth quarter ended November 30, 2020 was ($6.4 million) compared to a net loss of ($29.7 million) for the fourth quarter ended November 30, 2019. Net loss for the fiscal year ended November 30, 2020 was ($26.4 million) compared to a net loss of ($63.2 million) in the fiscal year ended November 30, 2019. The Company is committed to maintaining these positive trends.
  • The Company’s working capital position remains strong at $16.5 million as at November 30, 2020.
  • Subsequent to year-end, the Company successfully closed a $23 million bought deal offering.

Recent Corporate Highlights:

  • Launched CannMart.com into the USA offering Americans hemp derived CBD and smoking accessories.
  • Announced the addition of leading licensed producers to the CannMart.com platform: Auxly Cannabis Group, Hexo Corp and The Green Organic Dutchman Holdings (TGOD).
  • Received a standard processing licence from Health Canada for CannMart Labs Inc., our state-of-the-art BHO extraction facility.
  • Announced expansion to broaden our total addressable market and to evolve into a pre-eminent wellness company, connecting consumers to their wellness needs of tomorrow.

“We are pleased with the progress made by the team to achieve the highest recorded quarterly revenue for the company to date,” said Meni Morim, CEO of Namaste. “We achieved significant year-over-year growth of revenue as cannabis sales through CannMart’s distribution channels made an important contribution to the revenue stream. The Company is in a strong financial position today made possible from the considerable work undertaken in 2020 to lay the foundation for long term growth as Namaste continues its evolution to be the world’s foremost personalized wellness marketplace.”

For further details, the complete Financial Statements for the year-ended ended November 30, 2020 and the related Management’s Discussion & Analysis can be accessed on the Company’s SEDAR profile at www.sedar.com.

NON IFRS FINANCIAL MEASURES

Management evaluates the Company’s performance using a variety of measures, including “Net loss before income tax, depreciation and amortization” and “Adjusted EBITDA”. The non-IFRS measures discussed below should not be considered as an alternative to or to be more meaningful than revenue or net loss. These measures do not have a standardized meaning prescribed by IFRS and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with IFRS.

The Company believes these non-IFRS financial measures provide useful information to both management and investors in measuring the financial performance and financial condition of the Company.

Management uses these and other non-IFRS financial measures to exclude the impact of certain expenses and income that must be recognized under IFRS when analyzing consolidated underlying operating performance, as the excluded items are not necessarily reflective of the Company’s underlying operating performance and make comparisons of underlying financial performance between periods difficult. From time to time, the Company may exclude additional items if it believes doing so would result in a more effective analysis of underlying operating performance. The exclusion of certain items does not imply that they are non-recurring.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ada3b7a0-52a6-4007-917b-f0c10e3ed668

(i) Current and deferred income taxes, depreciation and amortization, and share-based compensation were excluded from the Adjusted EBITDA calculation as they do not represent cash expenditures.

(ii) Other income consisting of gain on disposal of subsidiary, interest income, realized gain on disposition of AFS investments, unrealized gain on derivatives and other miscellaneous non-recurring income were excluded from Adjusted EBITDA calculation.

(iii) Non-recurring costs related to restructuring and legacy issues were excluded from Adjusted EBITDA calculation.

(iv) Impairment loss relating to goodwill, customer list, domains and brand names were excluded from Adjusted EBITDA calculation.

(v) Impairment loss relating to receivable is a provision for expected credit loss to an associate and was excluded from Adjusted EBITDA calculation.

(vi) Share of associates loss, net of tax, is excluded due to lack of control.

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: [email protected]

Source: Namaste Technologies Inc

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to the Company building the world’s first personalized wellness marketplace and its commitment to continue to reduce its net losses are made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, Namaste’s ability to maintain momentum of expanding its business, its ability to broaden its total addressable market and to evolve into a recognized wellness company, the Company’s expectation that the nutraceutical and wellness market and potentially the market for psychedelics will develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products and brands will generate additional revenue, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the inability of the Company to develop its business as anticipated and to increase revenues and/or its profitable margin on such revenues, unanticipated changes to current regulations that would adversely impact the Company’s business and proposed business and other regulatory risks, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Source: Namaste Technologies Inc.

Release – Entravision (EVC) – Launches Fuego Radio Format in the Las Vegas and Palm Springs Markets


Entravision Launches Fuego Radio Format in the Las Vegas and Palm Springs Markets

 

SANTA MONICA, Calif.–(BUSINESS WIRE)– Entravision Communications Corporation:

WHAT:

Entravision Communications Corporation (NYSE: EVC), a leading global media and marketing technology company, today announced its Fuego Radio format is expanding into two new owned and operated stations in the Las Vegas (92.7 FM) and Palm Springs (103.5 FM) markets beginning on March 29, 2021. This follows Fuego Radio’s expansion into the Santa Barbara-Santa Maria affiliate (97.1 FM) market on January 6, 2021.

 

 

 

Fuego Radio presents a music mix ignited by today’s top trending global Latin Urban music movement mixed with Contemporary Hits, including recent chart topping artists such as Ariana Grande, Dua Lupa, Cardi B, Olivia Rodrigo, Drake, The Weeknd and Bruno Mars. In addition to hit music offerings, each morning Fuego Radio listeners can enjoy the antics of Edgar “Shoboy” Sotelo, on the popular Shoboy Show. This feel-good entertainment experience is real, relatable and fun and targets young adults that prefer entertainment in English with a Latin vibe. The Shoboy Show is also featured on Fuego Stations in Sacramento, Stockton and Modesto, California, Albuquerque, New Mexico, Salt Lake City, Utah and Harlingen, Brownsville and McAllen, Texas.

 

 

WHERE:

KRTO-FM, Santa Barbara-Santa Maria — as of January 6, 2021

 

KRRN-FM, Las Vegas and KPST-FM, Palm Springs — as of March 29, 2021

 

 

QUOTE:

“Following the expansion of our popular Fuego Radio format into the Santa Barbara-Santa Maria market in January, we are thrilled to also introduce this format into the Las Vegas and Palm Springs markets,” said Entravision’s Nestor Rocha, Vice President of Audio. “The Shoboy Show has been a great success in all of our markets, and we anticipate this momentum to continue in Las Vegas and Palm Springs as well.”

 

Contact for Affiliation:
Marisol Rodriguez
[email protected]
323-900-6310

Contact for Ad Sales:
Las Vegas:
Chris Jordan, SVP
[email protected]
702-507-1047

Palm Springs:
Bob McCauley, SVP
[email protected]
760-797-8401

Contact for Entravision:
Kimberly Esterkin
ADDO Investor Relations
[email protected]
310-829-5400

Source: Entravision Communications Corporation

Release – Great Bear Resources (GTBAF) – Doubles Vertical Extent of LP Fault Intersects High-Grade Gold


Great Bear Doubles Vertical Extent of LP Fault, Intersects High-Grade Gold at
942.20 m Downhole: 15.57 g/t Gold Over 3.05 m

 

March 29, 2021 – Vancouver, British Columbia,
Canada
– Great Bear Resources Ltd. (the “Company” or “Great Bear”, TSX-V: GBR; OTCQX: GTBAF) today reported results from its ongoing fully funded $45 million 2021 exploration program at its 100% owned flagship Dixie Project in the Red Lake district of Ontario.

Expansion of the LP
Fault

  • Deep drilling has doubled the
    drill-confirmed vertical extent
    of the LP Fault gold zone, which begins at bedrock surface, to approximately 800 vertical metres.  The area of ongoing grid drilling extends along 4 kilometres of strike length.  Figure 1 and Figure 2.
  • Three new 400 – 450 metre step-down holes drilled along 500
    metres of strike length all
    successfully intersected the continuation
    of the LP Fault host rocks and gold mineralization at depths of 700 – 820
    vertical metres
    .
  • Gold grades and mineralized
    zone thickness were better at depth
    on two of three tested drill sections.
  • Initial deep drilling tested below the most weakly
    mineralized segment
    of the LP Fault, formerly referred to as the “Gap” zone (February 13, 2020).
  • Large scale step-out drilling at depth,
    including below areas
    of high-grade gold mineralization
    , will continue throughout 2021.

High-Grade Gold in the First Deep LP Fault
Drill Holes

  • High-grade gold was intersected at depth in two of the three deep drill holes, with better grades and thickness than previously observed in the near surface.  All three deep drill holes contained multiple intervals of gold mineralization.  Table 1 and Table 2.
  • BR-260 is the deepest LP Fault drill hole to date.  It assayed 15.57
    g/t gold over 3.05 metres
    from 942.20 to 945.25 metres, within a broader interval of 1.08
    g/t gold over 70.25 metres
    from 906.15 to 976.40 metres.  Figure
    3
    and Figure
    4
    .
  • While high-grade intervals are the primary drill targets at these depths, the dual high-grade and bulk-tonnage character of the
    LP Fault gold zone remains strongly developed at depth
    .
  • Oriented core data collected from these initial deep holes will assist with determining controls to higher grade panels within the broad envelope of gold mineralization. 

Great Bear has now published results from 270 LP Fault drill holes and anticipates at least
130 additional
LP Fault drill holes will be completed by the end of 2021, for a total of at
least 400 drill holes
.

Chris Taylor, President and CEO of Great Bear said, “We drilled below the most weakly mineralized segment of the LP Fault with our first deep holes, and discovered better gold mineralization at depth.  After 270 drill holes we have yet to find the limits of the LP Fault’s gold mineralization.  Mesothermal gold systems of this type, particularly in the Red Lake area, can extend vertically over kilometres.  We are currently working with in-house and external modelers to finalize 2021 drill plans, and will provide guidance over the coming weeks on expected timing of delivery of initial estimates of mineral resources.”

Figure 1 (Top): Long section of the LP Fault zone showing the locations and depths of the new deep drill holes (labeled).
Figure 2 (Bottom) : Map of current drill results showing the location of the new deep drill holes.

 

 

Table 1: Drill holes released to date on section 21450 showing increased gold mineralization grades and widths with increasing depth in the former “Gap” zone.  See news releases of April 9, 2020 and May 4, 2020 for previously reported drill holes.
New results
from BR-260 in italics
.

Drill Hole

 

From (m)

To (m)

Width* (m)

Gold (g/t)

Vertical Depth (m)

BR-078

 

176.00

212.90

36.90

0.42

150

BR-097

 

255.00

259.00

4.00

1.39

220

 

and

391.70

393.50

1.80

3.49

335

BR-098

 

419.70

448.50

28.80

0.65

365

 

and

493.25

495.05

1.80

9.90

425

BR-260

 

906.15

976.40

70.25

1.08

760

(new)

including

942.20

945.25

3.05

15.57

790

* Widths are drill indicated core length, as insufficient drilling has been undertaken to determine true widths at this time.  Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts.  Interval widths are calculated using a 0.10 g/t gold cut-off grade with up to 3 m of internal dilution of zero grade. 

Table 2: New drill results from the first three deep holes into the LP Fault system along 500 metres of strike length in the “Gap” area.

Drill Hole

 

From (m)

To (m)

Width* (m)

Gold (g/t)

Section

BR-260

 

906.15

976.40

70.25

1.08

21450

 

including

929.30

948.00

18.70

3.33

 

 

and including

929.30

929.80

0.50

16.50

 

 

and including

942.20

945.25

3.05

15.57

 

 

and including

942.20

942.80

0.60

73.10

 

BR-261

 

624.85

638.50

13.65

0.57

21200

 

 

747.15

761.00

13.85

0.44

 

 

 

811.60

823.25

11.65

0.96

 

 

including

822.00

823.25

1.25

5.62

 

 

and

835.00

839.50

4.50

1.17

 

BR-262

 

871.00

876.50

5.50

1.19

21700

 

and

933.50

950.50

17.00

1.04

 

 

including

946.50

948.50

2.00

7.27

 

 

and including

946.50

947.50

1.00

12.30

 

* Widths are drill indicated core length, as insufficient drilling has been undertaken to determine true widths at this time.  Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts.  Interval widths are calculated using a 0.10 g/t gold cut-off grade with up to 3 m of internal dilution of zero grade. 

Figure 3: Section 21450 showing BR-260, the deepest drill hole in the LP Fault to date.  This section is located in what was formerly referred to as the “Gap” zone.

 

 

Figure 4:  The deepest drill hole in the LP Fault to date.  73.10 g/t gold over 0.60 metres at 942.20 metres down hole in BR-260 (790 metres vertical depth).  The shear-zone hosted disseminated high-grade gold with sparse accessory sulphides within a felsic volcanic host matches mineralization at shallower depths within the LP Fault.  Image is of a selected interval and is not representative of all gold mineralization on the property.

 

 

Great Bear’s progress can be followed using the Company’s plan maps, long sections and cross sections, and through the VRIFY model posted at the Company’s web site at www.greatbearresources.ca, which will next be updated in Q2 2021.  All LP Fault drill hole highlighted assays, plus drill collar locations and orientations can also be downloaded at the Company’s web site.

Drill collar location, azimuth and dip for drill holes included in this release are provided in the table below (UTM zone 15N, NAD 83):

Hole
ID

Easting

Northing

Elevation

Length

Dip

Azimuth

BR-260

456566

5635016

372

1200

-64

225

BR-261

456714

5634887

364

1284

-63

220

BR-262

456384

5635181

378

1110

-63

224

 

About the Dixie Project

The Dixie Project is 100% owned, comprised of 9,140 hectares of contiguous claims that extend over 22 kilometres, and is located approximately 25 kilometres southeast of the town of Red Lake, Ontario. The project is accessible year-round via a 15 minute drive on a paved highway which runs the length of the northern claim boundary and a network of well-maintained logging roads.

The Dixie Project hosts two principal styles of gold mineralization:

  • High-grade gold in quartz veins
    and silica-sulphide replacement zones (Dixie Limb, Hinge and Arrow zones)
    . Hosted by mafic volcanic rocks and localized near regional-scale D2 fold axes.  These mineralization styles are also typical of the significant mined deposits of the Red Lake district.
  • High-grade disseminated gold
    with broad moderate to lower grade envelopes (LP Fault).
      The LP Fault is a significant gold-hosting structure which has been seismically imaged to extend to 14 kilometres depth (Zeng and Calvert, 2006), and has been interpreted by Great Bear to have up to 18 kilometres of strike length on the Dixie property.  High-grade gold mineralization is controlled by structural and geological contacts, and moderate to lower-grade disseminated gold surrounds and flanks the high-grade intervals.  The dominant gold-hosting stratigraphy consists of felsic sediments and volcanic units.

About Great Bear

Great Bear Resources Ltd.
is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration.  Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 330 km2 of highly prospective tenure across 5 projects: the flagship Dixie Project (100% owned), the Pakwash Property (earning a 100% interest), the Dedee Property (earning a 100% interest), the Sobel Property (earning a 100% interest), and the Red Lake North Property (earning a 100% interest) all of which are accessible year-round through existing roads.

QA/QC and Core Sampling
Protocols

Drill core is logged and sampled in a secure core storage facility located in Red Lake Ontario.  Core samples from the program are cut in half, using a diamond cutting saw, and are sent to Activation Laboratories in Ontario, an accredited mineral analysis laboratory, for analysis. All samples are analysed for gold using standard Fire Assay-AA techniques. Samples returning over 10.0 g/t gold are analysed utilizing standard Fire Assay-Gravimetric methods.  Pulps from approximately 5% of the gold mineralized samples are submitted for check analysis to a second lab.  Selected samples are also chosen for duplicate assay from the coarse reject of the original sample.  Selected samples with visible gold are also analyzed with a standard 1 kg metallic screen fire assay.  Certified gold reference standards, blanks and field duplicates are routinely inserted into the sample stream, as part of Great Bear’s quality control/quality assurance program (QAQC).  No QAQC issues were noted with the results reported herein. 

Qualified Person and NI
43-101 Disclosure

Mr. R. Bob Singh, P.Geo, VP Exploration, and Ms. Andrea Diakow P.Geo, Exploration Manager for Great Bear are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release.

ON BEHALF OF THE BOARD

“Chris Taylor”

Chris Taylor, President and CEO

Investor Inquiries:
Mr. Knox Henderson
Tel: 604-646-8354
Direct: 604-551-2360
[email protected]
www.greatbearresources.ca

Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and
certain “forward-looking information” as defined under applicable Canadian and
U.S. securities laws. Forward-looking statements and information can generally
be identified by the use of forward-looking terminology such as “may”, “will”,
“should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”,
“plans” or similar terminology. The forward-looking information contained
herein is provided for the purpose of assisting readers in understanding
management’s current expectations and plans relating to the future. Readers are
cautioned that such information may not be appropriate for other purposes.

Forward-looking statements and information include, but are not
limited to, statements in respect of the proposed Offering including the
proposed use of proceeds, the closing date of the Offering, receipt of
regulatory and stock exchange approvals, the timing of future drilling,
exploration and budgets.

Forward-looking information are based on management of the
parties’ reasonable assumptions, estimates, expectations, analyses and
opinions, which are based on such management’s experience and perception of trends,
current conditions and expected developments, and other factors that management
believes are relevant and reasonable in the circumstances, but which may prove
to be incorrect.

Such factors, among other things, include: impacts arising from
the global disruption caused by the Covid-19 coronavirus outbreak, business
integration risks; fluctuations in general macroeconomic conditions;
fluctuations in securities markets; fluctuations in spot and forward prices of
gold or certain other commodities; change in national and local government,
legislation, taxation, controls, regulations and political or economic
developments; risks and hazards associated with the business of mineral
exploration, development and mining (including environmental hazards, industrial
accidents, unusual or unexpected formations pressures, cave-ins and flooding);
discrepancies between actual and estimated metallurgical recoveries; inability
to obtain adequate insurance to cover risks and hazards; the presence of laws
and regulations that may impose restrictions on mining; employee relations;
relationships with and claims by local communities and indigenous populations;
availability of increasing costs associated with mining inputs and labour; the
speculative nature of mineral exploration and development (including the risks
of obtaining necessary licenses, permits and approvals from government
authorities); and title to properties.

Great Bear undertakes
no obligation to update forward-looking information except as required by
applicable law. Such forward-looking information represents management’s best
judgment based on information currently available. No forward-looking statement
can be guaranteed and actual future results may vary materially. Accordingly,
readers are advised not to place undue reliance on forward-looking statements
or information

Release – Kratos Defense and Security Solutions (KTOS) – Autonomous Truck-Mounted Attenuator Named Infrastructure Game Changer


Kratos’ Autonomous Truck-Mounted Attenuator Named Infrastructure Game Changer by American Society of Civil Engineers

 

SAN DIEGO
March 29, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leading National Security Solutions provider and industry-leading provider of high-performance unmanned systems, today announced its Autonomous Truck-Mounted Attenuator (ATMA), a driverless version of mobile crash barriers, has been recognized by the 
American Society of Civil Engineers (ASCE) as an “Infrastructure Gamechanger” in the organization’s 2021 Report Card for American Infrastructure.  

ASCE combed through successful solutions across the major infrastructure sectors to identify the most innovative game changers and identified North Dakota’s pilot program utilizing Kratos’ ATMA which was developed in collaboration with  Royal Truck & Equipment, the nation’s largest producer of Truck Mounted Attenuator vehicles.

 

 

In the commercial highway maintenance industry, driving a Truck Mounted Attenuator (TMA) is one of the most dangerous task assignments in the work zone. The TMA vehicle functions as a human-driven mobile crash barrier following behind slow moving highway maintenance operations shielding those workers and equipment from errant drivers entering the work zone. Workers assigned to drive the TMA are at serious risk of lifelong injury if/when their TMA is impacted by another vehicle which can range from a family sedan to an 80,000-pound tanker truck traveling at 60 mph or more. In 
the United States, there are more than 12 crash-related fatalities every week in the road work zone.

Kratos’ Autonomous Truck-Mounted Attenuator, a driverless TMA used during road construction and highway maintenance vehicles, shields workers and equipment ahead from errant drivers entering the work zone. Hundreds of lives are lost in the 
U.S. annually with manned TMAs. By removing the human from the most dangerous assignment in mobile highway operations, Kratos’ ATMA has the potential to save lives and change this deadly trend.

Steve Fendley, President of Kratos Unmanned Systems Division, said, “Kratos is a leading innovator in development and application of affordable unmanned technologies. Our disruptive solutions have consistently been game changers in defense applications, and we are proud to now be recognized for providing a game-changing infrastructure solution that will save lives on America’s roadways.”

Rob Roy, Owner and President of Royal Truck & Equipment, said, “Royal is committed to continuously raising the bar with TMA truck safety. The ATMA, built in partnership with Kratos, is just one of the many ways we’re dedicated to improving and innovating work zone safety.”

Kratos Unmanned Systems’ ATMAs have driven more than 2,000 miles since launch in 2017, and in addition to the ongoing pilot in 
North Dakota, Kratos ATMAs are currently deployed in 
California
Colorado
Florida
Minnesota
Missouri, and 
Tennessee, as well as the 
United Kingdom.

About Royal Truck & Equipment: Founded in 1982,  Royal Truck & Equipment is North America’s largest manufacturer of TMA and Safety Trucks. The company is committed to producing trucks that meet or exceed the strictest safety standards in the industry. Visit www.royaltruckandequipment.com for more information.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information, please visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687

[email protected]

Source: Kratos Defense & Security Solutions, Inc.

Release – Helius Medical Technologies (HSDT)(HSM:CA) – FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients

 


FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients

 

Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus to generate electrical pulses for stimulation of the trigeminal and facial nerves via the tongue to provide treatment of motor deficits.

“MS is one of the most common neurological diseases in young adults. Today’s authorization offers a valuable new aid in physical therapy and increases the value of additional therapies for those who live with MS on a daily basis,” said Christopher M. Loftus, M.D., acting director of the Office of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health.

MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communications between the brain and other parts of the body. According to the National Institute of Neurological Disorders and Stroke, most people experience their first symptoms of MS between the ages of 20 and 40 and the disease occurs more frequently in women than in men. MS is a disease that affects people differently as it causes a variety of symptoms—such as problems with walking and balance—that can interfere with daily activities but can usually be treated or managed. The most common walking problem is unsteady, uncoordinated movements (known as ataxia) due to damage to the areas of the brain that coordinate muscle balance. People with severe ataxia generally benefit from the use of a cane, walker, or other assistive device. Physical therapy can also reduce walking problems.

The PoNS device is a portable, non-implantable device which delivers mild neuromuscular electrical stimulation to the dorsal surface of the patient’s tongue. It consists of a controller and a mouthpiece that are connected to each other by a cord. The mouthpiece is held lightly in place by the lips and teeth and the control unit is worn around the neck during a patient’s visit with a therapist. The controller sends signals to the mouthpiece placed on the tongue; receptors on the tongue send millions of neural impulses to the brain through natural pathways. Additionally, the therapist can connect the control unit to a computer and view usage data via software developed specifically for the PoNS device. The usage data gives the therapist information on how to improve a patient’s execution of therapy by identifying potential areas of missed or shortened sessions.

The FDA assessed the safety and effectiveness of the PoNS device through two clinical studies and a retrospective analysis of real-world data (RWD). In the first study, 20 patients with gait deficits due to MS participated in a randomized, double blind controlled trial where 10 patients used the PoNS device and the remaining 10 patients used a sham control device that did not deliver stimulation. The primary outcome measure was the Dynamic Gait Index (DGI) where the clinician scored an index of eight gait tasks. The DGI was assessed for a baseline, at two weeks, six weeks, 10 weeks, and 14 weeks. The results showed that the PoNS group on average achieved improvement in their DGI score of 7.95 at the end of the study, which was statistically significant and clinically significant, while the control group did not.

In the second study, the clinicians investigated the effects of the PoNS device with cognitive rehab and physical rehab in 14 patients with MS, who did not know whether they had the PoNS device or the sham control device, in a randomized controlled trial where seven patients used the PoNS device and the other seven used a sham device. Baseline evaluations included sensory organization tasks (SOT) and DGI scores. The PoNS device group showed a statistically significant improvement in SOT scores at 14 weeks compared to the baseline value. Analysis of DGI scores after 14 weeks showed no significant result.

The sponsor also provided a retrospective analysis of RWD collected with the PoNS device in MS patients in clinical rehabilitation settings. Patients who agreed to treatment were given 1-hr consultation, provided consent, and given baseline assessments of gait function using Functional Gait Assessment. No serious safety adverse events were reported in the clinical studies or retrospective analysis of RWD.

The PoNS device should not be used by patients with penetrating brain injuries, neurodegenerative diseases, oral health problems, chronic infectious diseases, unmanaged hypertension or diabetes, pacemakersand/or a history of seizures. Because the PoNS device delivers electrical stimulation directly to the surface of the tongue, precautions for use are similar to those for transcutaneous electrical nerve stimulation. Electrical stimulation should not be used if there is an active or suspected malignant tumor; in areas of recent bleeding or open wounds; or in areas that lack normal sensation. The PoNS device has not been tested on, and thus should not be used by, individuals under the age of 22 or who are pregnant. The PoNS device should not be used if a patient is sensitive to nickel, gold or copper.

Patients should use the PoNS device with caution, and electrical stimulation should only be used after seeking professional medical advice. For a full list of warnings and precautions to consider if using the PoNS device, please consult the device labeling.

The PoNS device was granted Breakthrough Device designation, which is a process designed to expedite the development and review of devices that may provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

The FDA reviewed the PoNS device through the De Novo premarket review pathway, a regulatory pathway for low-to moderate-risk devices of a new type. Along with this authorization, the FDA is establishing special controls for devices of this type, including requirements related to labeling and performance testing. When met, the special controls, along with general controls, provide reasonable assurance of safety and effectiveness for devices of this type. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA’s 510(k) premarket process, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.

The FDA granted marketing authorization of the Portable Neuromodulation Stimulator to Helius Medical, Inc.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Source: fda.gov

Release – Lineage Cell Therapeutics (LCTX) – Vitelliform Maculopathy Patient Treated With OpRegen Under Named Patient Compassionate Use

 


Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate Use

 

CARLSBAD, Calif.–(BUSINESS WIRE)–Mar. 29, 2021–

Lineage Cell Therapeutics, Inc.

(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced that a patient suffering from adult-onset vitelliform macular dystrophy (AVMD) had recently been treated with its lead product candidate, OpRegen, at
Hadassah-Hebrew University Medical Center in
Jerusalem, using a named patient compassionate use approval granted by the
Israeli Ministry of Health. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space and is currently being investigated in a 24-patient phase 1/2a clinical trial for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).

“Lineage is pioneering a new branch of medicine, consisting of the directed differentiation and transplant of specific cell types to replace damaged or dying cells with the goal of restoring or improving function lost to injury or disease,” stated Brian M. Culley, Lineage CEO. “With OpRegen, we are transplanting new retina cells to replace old cells that were lost or damaged to disease, with a goal of providing stability or functional improvements to vision. As outlined more fully on our recent earnings call, we believe there are many potential applications of Lineage’s core technology and intend this year to demonstrate that although we currently have three clinical-stage product candidates, those assets and our underlying platform may have utility in additional settings. For example, our RPE cells may be useful for treating additional retinal diseases, such as AVMD or Stargardt’s Disease. Similarly, our spinal cord program may be applicable to other conditions characterized by demyelination, and our oncology platform may have application across many different tumor types, depending on which antigen we elect to present to the patient’s immune system.”

Mr. Culley continued, “In this first instance, we treated a patient with AVMD, because it closely resembles dry AMD and similarly involves impaired RPE function and progressive vision loss. When the team at Hadassah approached us about treating their existing AVMD patient with OpRegen on a compassionate use basis, we were supportive of the request and saw it as an opportunity to investigate a new application for our OpRegen product candidate.”

This patient presented to the
Department of Ophthalmology at
Hadassah-Hebrew University Medical Center in late
December 2020 with sudden and severe visual acuity decreases in one eye. BCVA in the worse vision eye was measured at 20/200, compared to 20/40 in the patient’s contralateral eye. After an onset of blurred vision in 2018, evaluation and imaging diagnosed the patient as suffering from AVMD. Because AVMD is a disease of impaired RPE function leading to atrophy and shares similar characteristics to dry AMD, the team at Hadassah approached Lineage about the potential to treat this patient on a compassionate use basis. Lineage submitted a request on behalf of
Hadassah-Hebrew University Medical Center which was approved by the
Israeli Ministry of Health. Following approval from the University’s Ethics Committee, the patient was treated in
February 2021. The delivery of OpRegen RPE cells via pars plana vitrectomy was successful, with no complications arising during the procedure and the patient remains in follow-up.

About Adult-onset Vitelliform Maculopathy (AVMD)

AVMD is an eye disorder that can cause progressive vision loss and usually begins after age 40. AVMD affects an area of the retina called the macula, which is responsible for sharp central vision. The condition causes a fatty yellow pigment to accumulate in cells underlying the macula, eventually damaging the cells. Some people remain without symptoms throughout their life while others may slowly develop blurred and/or distorted vision, that can progress to central vision loss over time. There is currently no effective treatment for vitelliform macular dystrophy.

About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (vision from 20/65 to 20/250 with smaller areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen is a registered trademark of
Cell Cure Neurosciences Ltd., a majority-owned subsidiary of
Lineage Cell Therapeutics, Inc.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics
is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit
www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the potential conditions and diseases applicable to Lineage’s clinical-stage product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the
SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the
SEC
and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
([email protected])
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
([email protected])
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or David Schull
[email protected]
[email protected]
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.

Research coverage of Lineage Cell Therapeutics (LCTX) on Channelchek is provided by Noble Capital Markets, Inc. Please refer to the research disclosures on the most recent LCTX report for more information.

QuoteMedia (QMCI) – Margins Take A Hit As Revenues Ramp

Monday, March 29, 2021

QuoteMedia (QMCI)
Margins Take A Hit As Revenues Ramp

QuoteMedia, based in Fountain Hills, Arizona, provides cloud-based financial data, market news feeds, and financial software solutions.  Its customers include financial service companies, online brokerages, clearing firms, banks, media portals, public corporations and individual investors.  The company provides a single source solution providing products such as streaming quotes, charting, historical data, technical analysis, news and research.  Information can customized and provided to multiple platforms including terminals and mobile devices.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    In-line fourth quarter. Total company revenues were $3.266 million versus our $3.275 million estimate and operating cash flow, as measured by adj. EBITDA, was $58,000 versus our loss estimate of $21,000. Notably, the company’s Corporate Quotestream business had a very strong quarter, with revenues up 39%, which was somewhat offset by a 9% revenue decline in its Interactive Content segment revenues.

    Gross margins declined.  The year over year Q4 decline in gross margins from 52.0% to 41.6% reflects the revenue growth in its lower margin Corporate Quotestream business and the revenue weakness in its higher margin Interactive Content business. Management guided to an acceleration in revenue growth to 20% in subsequent quarters and for full year 2021, but gross margins are expected to be …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.